Outcome of Board Meeting held on May 12, 2026.
PFIZER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Pfizer Limited reported audited financial results for FY2026 with revenue from operations growing 10.4% to ₹2,519.65 crore from ₹2,281.35 crore. However, net profit declined 5.9% to ₹722.43 crore from ₹767.60 crore, impacted by exceptional items of -₹49.16 crore (personnel separation costs of ₹41.73 crore due to the Cipla distribution agreement and ₹7.43 crore for new labour code provisions). The Board recommended a final dividend of ₹75 per equity share (750%) totaling ₹343.11 crore, payable after August 4, 2026 to shareholders on record as of July 17, 2026. The 75th AGM is scheduled for July 28, 2026 via video conferencing. Statutory auditors B S R & Co. LLP gave an unmodified (clean) opinion on the financial statements. Cash and cash equivalents dropped significantly to ₹102.66 crore from ₹495.07 crore, largely due to increased fixed deposits and dividend payments.
The 10.4% revenue growth shows strong operational performance, but the net profit decline and exceptional items may concern investors seeking near-term profitability. The generous 750% dividend is positive for income-focused shareholders and signals management confidence in the company's financial health despite profit pressures.